Bicara Therapeutics Inc. Common Stock (BCAX) annual income statement — 4-year revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - |
| Operating Expenses | 174.06M | 155.6M | 82.39M | 39.89M | 37.66M |
| OpEx % of Revenue | - | - | - | - | - |
| Selling, General & Admin | 35.8M | 30.51M | 18.77M | 9.27M | 6.34M |
| SG&A % of Revenue | - | - | - | - | - |
| Research & Development | 111.11M | 125.1M | 63.62M | 30.62M | 31.31M |
| R&D % of Revenue | - | - | - | - | - |
| Other Operating Expenses | 1000K | 0 | 0 | 0 | 0 |
| Operating Income | -174.06M | -155.6M | -82.39M | -39.89M | -37.66M |
| Operating Margin % | - | - | - | - | - |
| Operating Income Growth % | - | -88.87% | -106.55% | -5.93% | - |
| EBITDA | -173.97M | -155.5M | -82.33M | -39.87M | -37.65M |
| EBITDA Margin % | - | - | - | - | - |
| EBITDA Growth % | -59.99% | -88.87% | -106.5% | -5.91% | - |
| D&A (Non-Cash Add-back) | 86K | 105K | 56K | 19K | 10K |
| EBIT | -169.67M | -155.6M | -82.39M | -39.89M | -37.73M |
| Net Interest Income | 16.94M | 17.87M | 14.58M | 1.31M | -108K |
| Interest Income | 16.94M | 17.87M | 14.58M | 1.31M | 4K |
| Interest Expense | 0 | 0 | 0 | 0 | 112K |
| Other Income/Expense | 16.94M | 17.87M | 14.58M | -12.09M | -188K |
| Pretax Income | -157.12M | -137.73M | -67.81M | -51.98M | -37.84M |
| Pretax Margin % | - | - | - | - | - |
| Income Tax | 93K | 217K | 187K | 5K | 1K |
| Effective Tax Rate % | -0.06% | -0.16% | -0.28% | -0.01% | -0% |
| Net Income | -157.31M | -137.95M | -68M | -51.98M | -37.84M |
| Net Margin % | - | - | - | - | - |
| Net Income Growth % | -70.38% | -102.88% | -30.8% | -37.36% | - |
| Net Income (Continuing) | -157.21M | -137.95M | -68M | -51.98M | -37.84M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.59 | -2.52 | -1.25 | -1.00 | -0.73 |
| EPS Growth % | -68.48% | -101.6% | -25% | -36.99% | - |
| EPS (Basic) | - | -2.52 | -1.25 | -1.00 | -0.73 |
| Diluted Shares Outstanding | 60.72M | 54.68M | 54.42M | 51.76M | 51.76M |
| Basic Shares Outstanding | 60.72M | 54.68M | 54.42M | 51.76M | 51.76M |
| Dividend Payout Ratio | - | - | - | - | - |
Quick answers to the most common questions about buying BCAX stock.
For fiscal year 2025, Bicara Therapeutics Inc. Common Stock (BCAX) reported total revenue of $0.0M.
Bicara Therapeutics Inc. Common Stock (BCAX) reported a net loss of $137.9M for the fiscal year ending 2025.